Haemonetics
261 hedge funds and large institutions have $3.87B invested in Haemonetics in 2018 Q1 according to their latest regulatory filings, with 46 funds opening new positions, 83 increasing their positions, 101 reducing their positions, and 25 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 3 → 6 (+3)
84% more first-time investments, than exits
New positions opened: 46 | Existing positions closed: 25
24% more capital invested
Capital invested by funds: $3.12B → $3.87B (+$750M)
6% more funds holding
Funds holding: 246 → 261 (+15)
2.68% less ownership
Funds ownership: 101.53% → 98.85% (-2.7%)
18% less repeat investments, than reductions
Existing positions increased: 83 | Existing positions reduced: 101
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$76.9M |
| 2 |
Capital Research Global Investors
Los Angeles,
California
|
+$59.7M |
| 3 |
Ameriprise
Minneapolis,
Minnesota
|
+$46.6M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$43.3M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$34.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HM
HealthCor Management
New York
|
-$65.4M |
| 2 |
Victory Capital Management
San Antonio,
Texas
|
-$63.1M |
| 3 |
VBA
Van Berkom & Associates
Montreal,
Quebec, Canada
|
-$56.5M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
-$46.7M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$43.3M |
HAE Hedge Fund Activity: Q1 2018 in Review
261 of the 4,364 institutional investors tracked by Wall St. Rank reported a position in Haemonetics (HAE) for Q1 2018, worth a combined $3.87B — up 24% from $3.12B a quarter earlier.
Buyers outnumbered sellers: 46 funds opened new HAE positions and 25 closed out — a net gain of 21 holders — while 83 added to existing stakes and 101 trimmed.
The largest buyer was Millennium Management, adding an estimated $76.9M. The largest seller was HealthCor Management, cutting an estimated $65.4M.
- 261 institutional investors held Haemonetics (HAE) as of Q1 2018, up from 246 in Q4 2017.
- Funds reported $3.87B of Haemonetics stock for Q1 2018, up 24% quarter-over-quarter.
- 46 funds opened new Haemonetics positions in Q1 2018 and 25 closed out, a net change of +21 holders.
- The largest Haemonetics buyer in Q1 2018 was Millennium Management, an estimated $76.9M added.
- The largest Haemonetics seller in Q1 2018 was HealthCor Management, an estimated $65.4M sold.
Based on aggregated 13F filings for Q1 2018.